Immunotherapy in Renal Cell Carcinoma: The Future Is Now

被引：181

作者：

Deleuze, Antoine ^{[1
,2
]}

Saout, Judikael ^{[1
]}

Dugay, Frederic ^{[1
,3
]}

Peyronnet, Benoit ^{[4
]}

Mathieu, Romain ^{[1
,4
]}

Verhoest, Gregory ^{[4
]}

Bensalah, Karim ^{[4
]}

Crouzet, Laurence ^{[2
]}

Laguerre, Brigitte ^{[2
]}

Belaud-Rotureau, Marc-Antoine ^{[1
,3
]}

Rioux-Leclercq, Nathalie ^{[1
,5
]}

Kammerer-Jacquet, Solene-Florence ^{[1
,5
]}

机构：

[1] Univ Rennes, EHESP Ecole Hautes Etud Sante Publ, IRSET Inst Rech Sante Environm & Travail, Inserm,UMR 1085, F-35000 Rennes, France

[2] Ctr Eugene Marquis, Dept Med Oncol, F-35000 Rennes, France

[3] Univ Hosp, Dept Cytogenet, F-35000 Rennes, France

[4] Univ Hosp, Dept Urol, F-35000 Rennes, France

[5] Univ Hosp, Dept Pathol, F-35000 Rennes, France

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 07期

关键词：

immunotherapy; immune checkpoint inhibitors; renal cell carcinoma; PD-1; PD-L1; ongoing trials; biomarkers; emerging drugs; TUMOR-CELLS; PD-L1; EXPRESSION; INTERFERON-ALPHA; SUNITINIB; NIVOLUMAB; EVEROLIMUS; RESISTANCE; INHIBITION; RECEPTORS; THERAPIES;

D O I：

10.3390/ijms21072532

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30% of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led to treatment remodeling emphasizing the role of the tumour microenvironment. However, long-term responses are rare with a high rate of resistance. New strategies are emerging to improve the efficacy and the emerging drugs are under evaluation in ongoing trials. With the different treatment options, there is an urgent need to identify biomarkers in order to predict the efficacy of drugs and to better stratify patients. Owing to the limitations of programmed death-ligand 1 (PD-L1), the most studied immunohistochemistry biomarkers, and of the tumor mutational burden, the identification of more reliable markers is an unmet need. New technologies could help in this purpose.

引用

页数：22

共 97 条

[41] External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study [J].

Heng, Daniel Y. C. ;

Xie, Wanling ;

Regan, Meredith M. ;

Harshman, Lauren C. ;

Bjarnason, Georg A. ;

Vaishampayan, Ulka N. ;

Mackenzie, Mary ;

Wood, Lori ;

Donskov, Frede ;

Tan, Min-Han ;

Rha, Sun-Young ;

Agarwal, Neeraj ;

Kollmannsberger, Christian ;

Rini, Brian I. ;

Choueiri, Toni K. .

LANCET ONCOLOGY, 2013, 14 (02) :141-148

[42] Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+regulatory T cells in renal cell carcinoma [J].

Inamura, Kentaro ;

Amori, Gulanbar ;

Yuasa, Takeshi ;

Yamamoto, Shinya ;

Yonese, Junji ;

Ishikawa, Yuichi .

CANCER MANAGEMENT AND RESEARCH, 2019, 11 :7021-7030

[43]

Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.21254]

[44] PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation [J].

Joseph, Richard W. ;

Millis, Sherri Z. ;

Carballido, Estrella M. ;

Bryant, David ;

Gatalica, Zoran ;

Reddy, Sandeep ;

Bryce, Alan H. ;

Vogelzang, Nicholas J. ;

Stanton, Melissa L. ;

Castle, Erik P. ;

Ho, Thai H. .

CANCER IMMUNOLOGY RESEARCH, 2015, 3 (12) :1303-1307

[45] Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma [J].

Kammerer-Jacquet, Solene-Florence ;

Deleuze, Antoine ;

Saout, Judikael ;

Mathieu, Romain ;

Laguerre, Brigitte ;

Verhoest, Gregory ;

Dugay, Frederic ;

Belaud-Rotureau, Marc-Antoine ;

Bensalah, Karim ;

Rioux-Leclercq, Nathalie .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07)

[46] A Consensus Molecular Classification of Muscle-invasive Bladder Cancer [J].

Kamoun, Aurelie ;

de Reynies, Aurelien ;

Allory, Yves ;

Sjodahl, Gottfrid ;

Robertson, A. Gordon ;

Seiler, Roland ;

Hoadley, Katherine A. ;

Groeneveld, Clarice S. ;

Al-Ahmadie, Hikmat ;

Choi, Woonyoung ;

Castro, Mauro A. A. ;

Fontugne, Jacqueline ;

Eriksson, Pontus ;

Mo, Qianxing ;

Kardos, Jordan ;

Zlotta, Alexandre ;

Hartmann, Arndt ;

Dinney, Colin P. ;

Bellmunt, Joaquim ;

Powles, Thomas ;

Malats, Nuria ;

Chan, Keith S. ;

Kim, William Y. ;

McConkey, David J. ;

Black, Peter C. ;

Dyrskjot, Lars ;

Hoglund, Mattias ;

Lerner, Seth P. ;

Real, Francisco X. ;

Radvanyi, Francois .

EUROPEAN UROLOGY, 2020, 77 (04) :420-433

[47] Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma [J].

Kim, Kyu-Tae ;

Lee, Hye Won ;

Lee, Hae-Ock ;

Song, Hye Jin ;

Jeong, Da Eun ;

Shin, Sang ;

Kim, Hyunho ;

Shin, Yoojin ;

Nam, Do-Hyun ;

Jeong, Byong Chang ;

Kirsch, David G. ;

Joo, Kyeung Min ;

Park, Woong-Yang .

GENOME BIOLOGY, 2016, 17 :80

[48] Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma [J].

Koshkin, Vadim S. ;

Barata, Pedro C. ;

Zhang, Tian ;

George, Daniel J. ;

Atkins, Michael B. ;

Kelly, William J. ;

Vogelzang, Nicholas J. ;

Pal, Sumanta K. ;

Hsu, JoAnn ;

Appleman, Leonard J. ;

Ornstein, Moshe C. ;

Gilligan, Timothy ;

Grivas, Petros ;

Garcia, Jorge A. ;

Rini, Brian I. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[49] Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma [J].

Kroeger, Nils ;

Klatte, Tobias ;

Chamie, Karim ;

Rao, P. Nagesh ;

Birkhaeuser, Frederic D. ;

Sonn, Geoffrey A. ;

Riss, Joseph ;

Kabbinavar, Fairooz F. ;

Belldegrun, Arie S. ;

Pantuck, Allan J. .

CANCER, 2013, 119 (08) :1547-1554

[50] Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions [J].

Lalani, Aly-Khan A. ;

McGregor, Bradley A. ;

Albiges, Laurence ;

Choueiri, Toni K. ;

Motzer, Robert ;

Powles, Thomas ;

Wood, Christopher ;

Bex, Axel .

EUROPEAN UROLOGY, 2019, 75 (01) :100-110

← 1 2 3 4 5 6 7 8 9 10 →